• Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact

Barry A. Friedman, PhD LLC

FDA Regulatory Compliance for the Pharmaceutical, Biotechnology and Medical Device Arenas

USP MICROBIAL REQUIREMENTS LACKING FOR MONOGRAPHS FOR PURIFIED WATER AND WATER FOR INJECTION

July 24, 2012 By Barry Friedman Leave a Comment

COMMENT

Often during webinars and seminars, the question is raised regarding the specifications for Purified Water (PW) and Water for Injection (WFI).  The USP has responded with an explanation as part of their series on Microbiological Frequently Asked Questions (FAQ).  Please read below to learn more about how one should develop specifications for microbial Water for Pharmaceutical Purposes.

“Because of the various uses of these waters, microbial requirements are not included in these monographs since this would require some uses to adhere to meaningless and/or inappropriate requirements.  Microbial guidelines are provided under the non-mandatory informational chapter Water for Pharmaceutical Purposes <1231>.  We recommend that you implement Alert and Action Levels no higher than, and preferably lower than, those listed in Water for Pharmaceutical Purposes <1231> based on the normal microbial performance trends in your water system.  The purpose of Alert and Action Levels is to trigger additional, rather than routine microbial measures. These additional control measures should avoid objectionable levels and types of microorganisms for the water’s use.”

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)

Related

Filed Under: FDA Compliance, Microbiological Issues, Regulatory Compliance Tagged With: Action Level, Alert Level, microbial requirements, purified water, USP, Water for Injection, Water for Pharmaceutical Purposes

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

New Reader? Learn More

Connect With Me:

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Webinar Registration & Information

FREQUENTLY ASKED QUESTIONS:

FDA Form 483 Frequently Asked Questions

USP General Chapter

USP General Chapter 62, Part II

TOP OBSERVATIONS:

FDA’s CDER LISTING OF TOP NINETEEN OBSERVATIONS FOR 2014

FDA CDER Most Frequent Form FDA 483 Observations Fiscal Year 2012

CDER MOST FREQUENTLY CITED DRUG OBSERVATIONS – FISCAL YEAR 2010

Top Posts:

Top Posts for 2012

Top Posts for 2013

Top Posts Year To Date

Recent Posts

  • Upcoming Microbiological Webinars
  • Microbiological Webinars
  • Microbiological Webinars 2020 (Upcoming)
  • General Chapter (USP<60>) on B. cepacia Complex to Issue December 1, 2019
  • Les Produits Chimiques B.G.R., Inc. Receives FDA Warning Letter (07/24/2018) for Failure to Perform Laboratory Testing

Categories

follow us in feedly
  • Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Thank You For Visiting Barry A. Friedman, PhD LLC - 2015

Welcome To My Blog!
Please enter your name and email below to receive my newsletter.
Your information will *never* be shared or sold to a 3rd party.